Peter Horby @peterhorby.bsky.social @PeterHorby Twitter profile

Last Seen Profiles

@remit86

@DjodjoMuhindo

@Shunrai_IE

@Weather2020

@antylose

@vsdkh56578

@hazmatas

@stw_pdg

@stwmaniax

@gulvemetn

@NestorRaff

@CamilleHBurton

@SuryaNTR999

@watashichan333

@ibubohay2

@luckwoooni

@ErnestinaN21498

@FireFamilyTrnsp

@AamilChere50898

@eucliffeew

@thefooliggy2

@saltywoundz

@konstantin28877

@thonychopper

@ChaleseTye48893

@KennethiaR77159

@willpagemusic

@apictom

@thatboyyy17

@KRasheda41483

@aslitzsche

@AnnyD98296

@Zizou1997ss

@FREEsportsystem

@stw_pdg

@45Onaziiii

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Dexamethasone saves lives in COVID-19. RECOVERY trial shows dexamethasone decreases risk of death in those needing oxygen by 20%, and by 35% in those on a ventilator. On the shelf, cheap and can be taken by everyone - a real breakthrough.

128

1K

4K

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

RECOVERY trial result: in COVID patients with low oxygen and inflammation, tocilizumab saves lives, keeps you off a ventilator, and gets you out of hospital quicker. Enormous thanks to the thousands of NHS staff and patients who made this possible. Pre-print coming very soon.

38

541

2K

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Asking whether the reaction to omicron is appropriate is valid. Questioning the science without understanding it is not. See thread.

Carl Heneghan

@carlheneghan

3 years

We’re in danger of letting bad science force us into a cycle of Covid restrictions

182

919

3K

50

456

2K

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

The RECOVERY Data Monitoring Committee reviewed data on patients randomised to convalescent plasma vs. usual care. The preliminary analysis based on 10,406 randomised patients with 1873 reported deaths shows no significant difference in the primary endpoint of 28-day mortality.

27

698

1K

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

To save lives?

Matthew Lesh

@matthewlesh

3 years

This is an insanely stupid idea — why ever produce a vaccine if your property rights will be stolen?

76

5

29

15

91

937

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

⏩ New RECOVERY trial result. Monoclonal antibody combination reduces deaths in seronegative patients hospitalised with COVID-19. - 9785 patients randomised - primary analysis population 3153 patients without own SARS-CoV2 antibodies detectable at randomisation (seronegative)

21

269

637

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Covid-19: Oxford University vaccine shows 70% protection. Oxford jab is far cheaper, and is easier to store and get to every corner of the world than the other two.

29

157

598

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

I’m immensely proud to be leading the new Pandemic Sciences Centre @UniofOxford The global scientific community have delivered huge societal benefits during the COVID pandemic. Our aspiration is to apply that same energy and innovation to prevent this ever happening again.

University of Oxford

@UniofOxford

3 years

🆕 | Oxford University announces the launch of a new centre of global research collaboration and excellence, the Pandemic Sciences Centre. The centre's mission will be to ensure that the world is better equipped to identify and counter future pandemic threats.

29

216

638

31

81

594

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Great news. Meta-analysis confirms that steroids reduce mortality of severe COVID-19.

17

224

580

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

RECOVERY Update - colchicine added today - still studying aspirin, convalescent plasma, REGN-CoV2, and tocilizumab - just passed 19,000 patients enrolled. Thank you everyone who has made this possible. Incredible effort that will soon give us more robust results.

14

124

567

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Results of DisCoVeRy trial of remdesivir in COVID now out. No significant effect of remdesivir on death, other clinical outcomes or viral kinetics. Big question about the role of this drug.

Remdesivir plus standard of care versus standard of care alone for the treatment of patients...

No clinical benefit was observed from the use of remdesivir in patients who were admitted to hospital for COVID-19, were symptomatic for more than 7 days, and required oxygen support.

www.thelancet.com

35

245

529

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report now published @NEJM #recoverytrial

17

247

521

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Carl Henengans says "'I've been doing this job for 25 years and I can tell you can't establish a quantifiable number in such a short time frame." Yes you can. Prof Henengans has not been doing phylogenetic and mathematical modelling of infectious disease dynamics for 25 years.

Dr Zoe Harcombe, PhD

@zoeharcombe

4 years

Cancelling Christmas with the claim of a new variant? Show us the evidence! @carlheneghan

68

325

1K

33

96

486

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

New RECOVERY result. In patients hospitalised with COVID-19, azithromycin did not provide any clinical benefit. 28 day mortality (19% vs 19%) (rate ratio 1·00; 95% confidence interval [CI] 0·90-1·12; p=0·99). No effect on secondary outcomes either.

12

181

497

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

New RECOVERY result: Baricitinib 8156 patients randomly allocated to receive usual care plus baricitinib versus usual care alone. 28-day mortality lower in patients allocated baricitinib: 513/4148 (12%) vs 546/4008 (14%) (age-adjusted rate ratio 0.87; 95% CI 0.77-0.98; p=0.026)

13

175

490

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

RECOVERY publication on hydroxychloroquine finally out. Hydroxychloroquine is not effective in hospitalised COVID patients. Disappointing, but allows us to focus our efforts on promising new treatments.

20

219

436

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Current concerns are based on "good intelligence, clear thought and strong evidence." I'm afraid this article is not.

16

39

431

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Full results of RECOVERY convalescent plasma trial now available. -11,558 hospitalised patients randomised -5,795 allocated to high-titre plasma -Sadly, we no saw no clinical benefits

9

237

423

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Good news for patients - First monoclonal antibody treatment for COVID-19 approved for use in the UK

First monoclonal antibody treatment for COVID-19 approved for use in the UK

The Medicines and Healthcare products Regulatory Agency (MHRA) has today given approval for the first monoclonal antibody treatment for the prevention and treatment of COVID-19 in the UK.

www.gov.uk

7

128

417

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Great news: REGEN-COV2 monoclonal antibody cocktail to be tested in RECOVERY. High SARS-COV-2 viral load is associated with worse clinical outcomes, so thrilled to be testing this potent antiviral. Lancet Respir Med. 2020 Sep;8(9):e70. Science 2020;369:1010-1014

12

148

398

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Potential health and economic impacts of dexamethasone treatment for patients with COVID-19 Between July and December 2020, dexamethasone is estimated to have saved 12,000 (4,250 - 27,000) lives in the UK and 650,000 (240,000 - 1,400,000) globally.

9

193

390

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Dexamethasone reduced deaths by 1/3rd in ventilated patients (rate ratio 0.65 [95% CI 0.48 to 0.88]; p=0.0003) and by 1/5th in patients receiving oxygen only (0.80 [0.67 to 0.96]; p=0.0021). No benefit in patients not requiring respiratory support (1.22 [0.86 to 1.75; p=0.14).

15

177

382

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

14

208

381

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Oh look.....

David Shariatmadari

@D_Shariatmadari

4 years

This aged well

21

81

611

13

101

370

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

So a treatment for hospitalised COVID-19 patients who require respiratory support. Globally, a lot of lives will be saved. Hugely indebted to all the patients, relatives and NHS workers who made this possible.

23

79

363

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

9

166

367

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

This is not an "inevitable seasonal surge in Covid and other respiratory pathogens". 1. It is summer in South Africa. As many places, SA has had both summer and winter waves. Seasonal influence on non-endemic infections is weak

10

64

352

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

🎂Today is exactly one year since we randomised the first patient to the RECOVERY trial - 19th March 2020. An astonishing contribution to global health by thousands of NHS and NIHR staff, and tens of thousands of patients. Join our anniversary webinar on 7th April.

Tropical Medicine Oxford

@TropMedOxford

4 years

Join our TropMed webinar #RECOVERYtrial , One year on. Learn the inside story from the trial leaders, a clinician and a patient involved in the study. Wed 7th April at 9:00BST @ISARIC1 @Oxford_NDPH @ERGO_Horby @OUCRU_Vietnam Register

3

23

41

6

114

347

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

RECOVERY closes colchicine arm - no benefit in hospitalised COVID patients. Disappointing, but nevertheless it advances our care of COVID patients. Full results to follow ASAP. Still testing aspirin, MAb, baricitinib

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

Statement from the RECOVERY trial chief investigators, 5 March 2021

www.recoverytrial.net

8

154

349

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY). In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes.

11

145

347

Peter Horby @peterhorby.bsky.social

@PeterHorby

2 years

Monkeypox epidemiology - is the simultaneous detection of multiple cases in multiple locations more consistent with dispersion from a single super-spreading event (such as a festival), or from multiple unrecognised chains of community transmission?

21

71

339

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

It is unbelievable, as it is not true. Dose was based on detailed pharmacokinetic modelling of chloroquine and hydroxychloroquine.

James Todaro, MD

@JamesTodaroMD

4 years

1/ As unbelievable as it sounds, it appears the RECOVERY trial confused hydroxy*chloroquine* (HCQ) w/ the drug class hydroxy*quinolines* The investigators of RECOVERY said they based HCQ dosing off treatment of amoebic dysentery, which is why they decided 2,400mg of HCQ on day 1

151

848

1K

63

100

340

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Hydroxychloroquine and chloroquine should not be used to treat hospitalised COVID patients. Meta-analysis of 14 unpublished trials (1308 patients) and 14 publications/preprints (9011 patients).

13

148

329

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Independent confirmation of RECOVERY results. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19

13

140

298

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England | CMMID Repository

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Combining multiple behavioural and epidemiological data sources with mathematical models, we analysed the transmissibility and impact of novel SARS-CoV-2 Variant of Concern 202012/01 in England.

cmmid.github.io

25

164

307

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Pre-print now out. Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.

19

175

303

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

🔥 RECOVERY result Aspirin 14892 COVID patients randomised to aspirin vs. usual care alone - no significant difference in 28-day mortality (17% aspirin vs. 17% usual care; rate ratio 0.96 [95% CI 0.89-1.04]; p=0.35). Pre-print imminent.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

www.recoverytrial.net

22

146

298

Peter Horby @peterhorby.bsky.social

@PeterHorby

2 years

RECOVERY pre-print out. In hypoxic hospitalised COVID-19 patients requiring either no oxygen or simple oxygen only, higher dose corticosteroids significantly increased the risk of death compared to usual care, which included low dose corticosteroids.

Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring...

Background Low-dose corticosteroids have been shown to reduce mortality for hypoxic COVID-19 patients requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical...

www.medrxiv.org

3

134

295

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Latest RECOVERY publication: Colchicine is not beneficial in patients admitted to hospital with COVID-19.

4

99

290

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

More good news. Antibodies to SARS-CoV-2 are associated with protection against reinfection

1

69

285

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

RECOVERY had all three: 1. All plasma tested with an assay ≥ 99% sens and spec for SARS-CoV-2 Abs 2. No mortality benefit in patients allocated to CP ≤4 days from illness onset (n=1908). 3. All plasma units far exceeded FDA definition of "high titre"

Arturo Casadevall

@ACasadevall1

3 years

Sadly not a scientific win. Many of the early trials including RECOVERY were not designed taking into account 100 years of experience with antibody therapies - see Of the principles recovery had 1, maybe 3, but not 2

4

11

29

12

89

280

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Amy, push on with confidence. I got BCD (yes D!) A level grades. Not what I needed from the lowest offer I got; but doctor I am, professor now @ Oxford.

Amy Turnbull

@itsamyturnbull

4 years

I tell you one thing. Yes I didn’t get the grades I want, and yes I did get rejected from both my firm and insurance choices. But there is nothing stopping me from becoming a doctor some day

187

367

9K

3

23

269

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Results of SOLIDARITY trial now published in NEJM. Remarkable achievement, with clear, albeit disappointing, results. Challenging to find an effective antiviral against SARS-CoV-2.

15

100

267

Peter Horby @peterhorby.bsky.social

@PeterHorby

2 years

If Legionella is confirmed as the cause of the pneumonia cases in Argentina, this is good news for public health. Common organism, common to see outbreaks, not more than a localised threat, treatable, and we know how to neutralise the source.

Tulio de Oliveira

@Tuliodna

2 years

Argentina health department confirmed the ‘unknown pathogen’ of the pneumonia cases as Legionela pneumonia bacteria today. Fast action and transparency to fight outbreaks. Genomes should follow in the next few days 🇦🇷

24

346

968

11

56

254

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

First results from RECOVERY trial in COVID - hydroxychloroquine

15

165

247

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Dex?

Jeremy Farrar

@JeremyFarrar

4 years

Still no agreement on a name - negotiations continue.

369

14

923

13

11

254

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

RECOVERY trial goes international. Wonderful to welcome our colleagues in Nepal and Indonesia to the RECOVERY trial of COVID treatments. First patients enrolled in Nepal - thank you Teku Hospital, Patan Hospital, @BasnyatBuddha , Nepal Health Research Council.

7

67

251

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Another RECOVERY trial milestone. 2000 COVID patients enrolled in comparison of convalescent plasma versus usual NHS care. 1000 vs 1000. Massive thanks to all the plasma donors, NHS staff, NHSBT and patients. We need to keep on recruiting - #answerbyXmas

6

54

253

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

4. The rapid growth rate in infections was quickly and correctly predicted, precisely based on real world data from South Africa. Fast growth rates offset reduced severity. Omicron cases are doubling every 2 days. A halving of severity would be completely discounted in 2 days

4

46

237

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Good result on use of wolbachia to reduce dengue transmission. Congratulations Katie Anders and team. 'Miraculous' mosquito hack cuts dengue by 77% - BBC News

'Miraculous' mosquito hack cuts dengue by 77%

Infecting the mosquitoes with a different bug slams the brakes on dengue fever, trial finds.

www.bbc.co.uk

2

74

237

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

If they were a scientist they would not look at one graph in isolation and reach a conclusion, they would look at the totality of evidence - and say “yes”.

10

23

225

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

RECOVERY has shown that it is possible to massively accelerate medical advances and massively decrease costs. Estimated cost of £250 per patient enrolled - a fraction of other clinical trials.

David Grainger

@sciencescanner

3 years

The speed of therapeutic innovation cominhg from RECOVERY trial is sensational! This should be the model for every common disease from heart disease to Alzheimer’s, osteoporosis to IBD Nothing would accelerate innovation for patients faster. Who’s going to be first?

7

18

56

3

46

230

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Please, no regrets. Donating plasma has made a major contribution to advancing COVID care. It might have worked but the trial was needed to know for sure. A negative result is hugely important. We learn about COVID and refocus our efforts.

Manick Govinda

@manick62

4 years

#Covid19 : I’m really sad to read this 😢 I have no regrets though for taking part in the research trials. Onwards and upwards to mitigating, minimising and managing this bastard virus. Convalescent plasma no benefit to hospital patients - BBC News

16

12

49

8

32

222

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

2. Other respiratory viruses are not increasing in UK. See line with the black triangles in figure. "The overall influenza positivity is low ...Respiratory syncytial virus (RSV) positivity decreased ... Rhinovirus positivity remained stable at 11.4% in week 49."

6

33

219

Peter Horby @peterhorby.bsky.social

@PeterHorby

5 years

RECOVERY Trial of treatments for COVID-19 in the UK: website now active

15

143

212

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

5. Hospitalisations lag cases by several weeks. Hospitalisations are now increasing in SA.

8

39

210

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Updated information on SARS-CoV-2 variant B.1.1.7 Results from the cohort study found no statistically significant difference in hospitalisation and 28-day case fatality between cases with the variant (VOC 201212/01) and wild-type comparator cases.

12

82

211

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Just after 2pm today, RECOVERY passed a landmark of 10,000 patients recruited in January alone. An extraordinary contribution by patients and by people working under enormous pressure in hospitals across the UK. Thank you for advancing COVID care. #NHS #NIHR #UKRIfunding

7

34

213

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Although negative, this result is incredibly important and moves forward the treatment of COVID. This was only possible thanks to the generosity of recovered patients and the willingness of current patients to contribute to advancing medical care. We owe you all a great debt.

3

21

197

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

3. Changes in the virus can explain the multiplicative increase. "Omicron SARS-CoV-2 infects and multiplies 70 times faster than the Delta variant and original SARS-CoV-2 in human bronchus"

6

39

186

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

BBC News - Dexamethasone is first life-saving coronavirus drug

8

87

183

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

As well as preventing infections and severe disease, COVID vaccination also reduces household transmisson. Get vaccinated to protect yourself and others.

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England | NEJM

In this study involving household contacts of persons with laboratory-confirmed Covid-19, the risk of household transmission was 40 to 50% lower among household contacts of index patients who had ...

www.nejm.org

2

63

185

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Incredible to see geographic (economic?) differences in pandemic disease risk virtually unchanged 100 years later.

9

111

183

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

This is where we need to be headed

Vala Afshar

@ValaAfshar

4 years

In the Netherlands, a quarter of all journeys are made by bicycles. In terms of environmental benefit, this is equivalent to planting 54 million trees a year. 🇳🇱🚲🌳

2

106

215

5

24

180

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Most of the assessments of CP failed to take into account the almost 80 year history of the vital importance of randomisation and the inherent unreliability of observational data.

3

27

180

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

B1.1.7 variant update from LSHTM: frequency of the variant has grown substantially in all regions of England.

6

79

179

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

13,000 participants now in the RECOVERY trial of COVID-19 treatments. Incredible achievement - thank you everyone. Need to keep pushing to get answers on the great portfolio of treatments being tested now - azithromycin, convalescent plasma, monoclonal antibody and tocilizumab.

7

49

175

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Allowing widespread use of unproven treatments creates confusion and undermines chances of improving care through proper science. US allows emergency use of blood plasma treatment for coronavirus patients

13

69

171

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Fabulous news and an incredible achievement. Oxford/AstraZeneca Covid vaccine approved by UK regulator

Oxford/AstraZeneca vaccine rollout plan changed following approval

Concern over move to give millions first jab with a wait of up to 12 weeks for second dose

www.theguardian.com

5

23

169

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Amazing. Brilliant work by Vietnam (no deaths) and by Bệnh viện Bệnh nhiệt đới. Vietnamese determination at its very best. BBC News - Patient 91: How Vietnam saved a British pilot and kept a clean Covid-19 sheet

Patient 91: How Vietnam saved a British pilot and kept a clean Covid-19 sheet

Stephen Cameron spent 68 days on a ventilator but beat the odds to survive coronavirus.

www.bbc.co.uk

4

51

168

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

⏩40,000 COVID patients now recruited to RECOVERY trial. Phenomenal effort by front-line staff @NHSuk , @NIHRresearch , @NHSDigital , @Oxford_NDPH , @NDMOxford Remarkable contribution by patients and their families. Together improving COVID care & saving lives. Thank you.

4

45

163

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

No benefit from high-titre convalescent plasma in critically adults with COVID. REMAP-CAP COVID-19 Convalescent Plasma Randomized Clinical Trial via @JAMA_current part of @JAMANetwork

7

66

161

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

NIHR has been absolutely critical to the success of RECOVERY - NIHR a national treasure.

1

30

159

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

RECOVERY manuscript now fully published: Casirivimab and imdevimab in patients admitted to hospital with COVID-19 Randomised trial of 9785 patients. Casirivimab and imdevimab reduces mortality in seronegative patients.

6

51

157

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Result from Roche trial of tocilizumab in COVID relate pneumonia out today: unfortunately did not show a benefit.

9

134

153

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Molnupiravir is now being evaluated in RECOVERY. Whilst we have proof-of-concept, through monoclonals, that antivirals can be beneficial in severe COVID, we are struggling to find effective antivirals. Combination antiviral therapy the way forward?

Molnupiravir to be investigated by the RECOVERY Trial as a potential treatment for patients...

www.recoverytrial.net

24

58

152

Peter Horby @peterhorby.bsky.social

@PeterHorby

8 months

Avian flu makes me nervous ++ We need to be ready for it becoming more transmissible between humans. Between 2020–2023, 26 countries reported >48 mammal species infected by H5N1. Geographic area and No. of species affected has increased. /eid/article/30/3/23-1098_article

13

53

151

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

NI nearly out of ICU beds. A harsh lesson that the virus behaves as we know it will - don’t be fooled by false optimism, fake news or conspiracies.

Debbie Keatley 💙

@DebbieKeatley

4 years

@JeremyFarrar @OECD Today NI has 9 ICU beds available, of which 6 are in paediatric ICU, 1 in cardiac ICU. Essentially there are now 2 ICU beds remaining in NI for COVID cases.

2

15

31

11

80

142

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

RECOVERY 25k: I know we keep saying it - but can't say it enough - an astonishing achievement by the NHS, NIHR, DHSC, patients and their families. Making an unparalleled contribution to global health at a time of crisis.

Martin Landray

@MartinLandray

4 years

RECOVERY Trial Update: - 25,000 patients enrolled, incl: - 2800 to tocilizumab vs. usual care - 11,100 to convalescent plasma vs. REGN-COV2 vs. usual care - 5,200 to aspirin vs. usual care These are such difficult times. Getting answers is so important. Huge thanks to everyone.

11

93

428

8

36

148

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

“If you need to be right before you move, you will never win.”

Irfan Dhalla

@IrfanDhalla

4 years

Most of us have seen this video by now. But worth watching again. The advice is just as relevant as we hit new peaks in many countries as it was at the beginning.

29

477

1K

4

49

140

Peter Horby @peterhorby.bsky.social

@PeterHorby

2 years

New placebo controlled trial results do not support the use of ivermectin in outpatients with mild to moderate COVID-19. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19

Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate...

This randomized clinical trial compares the efficacy of ivermectin vs placebo in shortening symptom duration among adult outpatients in the US with symptomatic mild to moderate COVID-19.

jamanetwork.com

18

53

132

Peter Horby @peterhorby.bsky.social

@PeterHorby

1 year

The burden on those making grant applications must be reduced. It is a major barrier, especially to less well resourced researchers. In a recent application I was involved in, the actual science started on page 100 of 168 pages.

Science and Innovation at Cancer Research UK

@CRUKresearch

1 year

As part of the Research Funders Policy Group, we’re working with other UK research funders to share best practice, align policy & reduce bureaucracy. Find out more: @AMRC @TheBHF @NIHRresearch @RAEngNews @royalsociety @UKRI_News @wellcometrust

0

2

11

6

33

131

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Lovely evening with my son at Viet Nam national day celebrations. Thank you 🇻🇳

2

137

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

The team has been truly amazing - a master class in trial management.

Martin Landray

@MartinLandray

4 years

Enormously proud of the team who have coordinated the #RECOVERYtrial - from first protocol to first proven benefit in 3 months. An extraordinary effort delivering an important result. @Oxford_NDPH @NDMOxford @OxfordMedSci @OxfordBRC

20

113

476

14

18

134

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

We also continue to study REGN-CoV2, tocilizumab, aspirin and colchicine.

12

20

136

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

There was A LOT of resistance to studying steroids - that’s what you get when there is equipoise and weak evidence

Graham Cooke

@grahamscooke

4 years

This is really great news. Important to remember how many people early on believed that steroids would be harmful, based on studies of other diseases, and were reluctant to consider randomisation.

5

21

92

9

30

132

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

POTUS, like many thousands of other COVID patients, is benefiting from those patients who went before and selflessly volunteered to be in a clinical trial. Everyone can give back by supporting clinical trials in anyway they can. Let's find better treatments for everyone.

Kai Kupferschmidt

@kakape

4 years

So Trump is now also receiving dexamethasone. @WHO guidelines very clear that it is to be used only “in patients with severe and critical #COVID19 ”. Guidelines incl. “conditional recommendation not to use corticosteroid therapy in patients with non-severe #COVID19 ”.

106

1K

2K

9

39

134

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

>14,000 patients in RECOVERY. Remarkable effort by thousands of people - a triumph of the NHS working under extreme pressure. Together we will find new treatments.

Tom Poyner

@tom_poyner

4 years

The pandemic has further highlighted the importance of large RCTs in guiding best clinical practice. Hats off to everyone across the UK involved in the RECOVERY trial. The rapid response has been truly remarkable 👏👏

0

1

7

2

23

127

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

7

66

126

Peter Horby @peterhorby.bsky.social

@PeterHorby

2 years

Cases of severe pneumonia of unknown aetiology reported from Argentina. Cases in healthcare workers are a concerning signal - could indicate person-to-person transmission or a point source (such a legionella).

Briefing Note: Cases of pneumonia due to unknown cause - Tucumán Argentina

On 30 August 2022, the Ministry of Health of Argentina informed to the Pan American Health Organization/World Health Organization (PAHO/WHO) of the notification by the Ministry of Public Health of...

www.paho.org

5

56

124

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

A privilege to accept the award on behalf of the enormous and exceptional RECOVERY collaborative group. Massive thanks to the trial team @UniofOxford led by Professor Richard Haynes and the many thousands of dedicated people at @NHSuk @NIHRresearch @DHSCgovuk

The BMJ

@bmj_latest

3 years

Congratulations to The RECOVERY Collaborative Group for their paper Dexamethasone in Hospitalized Patients with Covid-19, and winning UK Research Paper of the Year @PeterHorby @MartinLandray #TheBMJAwards

6

46

231

2

17

126

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Encouraging result. Molnupiravir reduced risk of hospitalisation or death by about 50%. 7.3% of patients who got molnupiravir were hospitalized or died through Day 29 following randomization (28/385), compared to 14.1% placebo-treated patients (53/377); p=0.0012

6

30

121

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Three studies show COVID-19 vaccines don't raise miscarriage risk

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons | NEJM

Many pregnant persons in the United States are receiving messenger RNA (mRNA) coronavirus disease 2019 (Covid-19) vaccines, but data are limited on their safety in pregnancy. From December 14, 2020...

www.nejm.org

3

45

123

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

RECOVERY Trial to investigate sotrovimab as a possible treatment for hospitalised COVID-19 patients. Sotrovimab, a monoclonal antibody that targets a conserved region of the coronavirus spike protein, retains activity against the Omicron variant.

RECOVERY Trial to investigate sotrovimab as a possible treatment for hospitalised COVID-19 patients

www.recoverytrial.net

3

40

120

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Just call me Pete. Thanks Charlotte

Rupert Beale

@bealelab

3 years

@charlot_summers @PeterHorby @MartinLandray You have to call them Sir now.

2

0

6

19

3

123

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

Key figure from monoclonal treatment pre-print that will come out later today

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

⏩ New RECOVERY trial result. Monoclonal antibody combination reduces deaths in seronegative patients hospitalised with COVID-19. - 9785 patients randomised - primary analysis population 3153 patients without own SARS-CoV2 antibodies detectable at randomisation (seronegative)

21

269

637

8

53

124

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis

11

61

120

Peter Horby @peterhorby.bsky.social

@PeterHorby

3 years

RECOVERY Colchicine result out now as pre-print 11340 patients hospitalised with COVID-19 randomised to colchicine vs usual care Unfortunately no evidence of clinical benefit in primary or secondary outcomes, or in any patient subgroups.

4

44

123

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

Monoclonal antibodies now being tested in RECOVERY trial. We are rolling this experimental therapy out to hospitals as quickly as we can, so we can find out if it works as quickly as we can.

Wellcome

@wellcometrust

4 years

⚡️ They're transforming treatment for many diseases. Could #Covid19 be next? ➡️

0

5

8

10

42

122

Peter Horby @peterhorby.bsky.social

@PeterHorby

4 years

18% convalescent plasma vs. 18% usual care alone; risk ratio 1.04 [95% confidence interval 0.95-1.14]; p=0.34. Follow-up of patients is ongoing and final results will be published as soon as possible.

4

30

118